Company Profile

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Latest News

AECOM selected to design New Lisbon Airport

Business Wire • 07/27/2026

Christopher Nolan’s The Odyssey Continues its Journey in IMAX with Record-Breaking $48 Million Second Weekend

Business Wire • 07/27/2026

Ipsen’s Bylvay fails in Phase III biliary atresia study

Clinical Trials Arena • 07/27/2026

Rothschild & Co Redburn Adjusts PT on Honeywell International to $216 From $214, Keeps Neutral Rating

MT Newswires • 07/27/2026

JPMorgan Adjusts PT on Honeywell International to $262 From $250, Maintains Overweight Rating

MT Newswires • 07/27/2026